杜皮卢马布改善了儿童2型喘中的肺功能参数:VOYAGE研究
Leonard B Bacharier1, Theresa W Guilbert2, Constance H Katelaris3
1Division of Allergy, Immunology and Pulmonary Medicine, Monroe Carell Jr Children's Hospital at Vanderbilt University Medical Center, Nashville, Tenn.
The journal of allergy and clinical immunology. In practice
|December 13, 2023
概括
在患有中度至重度2型喘的6至11岁儿童中,dupilumab显著改善了肺功能. 在52周的时间里,这种治疗对肺生长和功能产生了持续的好处.
科学领域:
- 儿科肺病学 儿科肺病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿童不控制的喘会阻碍肺部发育,可能导致长期健康问题.
- 由IL-4和IL-13驱动的2型炎症是中度至重度喘的关键因素.
- 杜皮卢马布是一种单克隆抗体,向IL-4受体α子单元,从而抑制IL-4和IL-13信号传递.
研究的目的:
- 评估dupilumab在改善中度至重度喘的6至11岁儿童的肺功能方面的疗效.
- 评估dupilumab对儿科喘患者肺生长和发育的长期影响.
- 分析螺旋测量参数,并确定从dupilumab治疗中受益最多的子组.
主要方法:
- 进行了一项为期52周的随机,双盲,安慰剂控制的第三期试验 (LIBERTY ASTHMA VOYAGE).
- 患有中度至重度喘的儿童每隔两周接受额外的dupilumab或安慰剂.
- 在2型喘患者中,使用螺旋计评估肺功能,包括1秒内强制呼气体积 (FEV1) 和部分呼出的氧化 (FeNO).
主要成果:
- 杜皮卢马布治疗导致从第2周开始,并持续52周,支气管扩展前和后的百分比预测的1秒内强迫呼气量 (ppFEV1) 显著改善.
- 在第52周,ppFEV1与安慰剂的最小平方平均差异为支气管扩张前的7.79个百分点 (P < .001) 和支气管扩张后的4.37个百分点 (P = .01).
- 在所有分析的人群中,在其他肺功能参数中观察到持续的改善,包括强迫生命能力 (FVC) 和FEV1/FVC比率.
结论:
- 杜皮卢马布在6至11岁的儿童中,在多种肺功能测量中显示出显著和持续的改善,这些儿童患有不受控制的中度至重度2型喘.
- 这些发现表明dupilumab是一种有效的治疗选择,可以改善肺功能,并可能减轻与儿科喘肺生长受损相关的长期并发症.
- 早期和持续的肺功能改善突出显示了dupilumab在治疗儿科喘方面的潜力及其对肺部发育的影响.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
317
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
317
01:23Inhaled Medications
279
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
279
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
271
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
271
01:17Drugs Used in Lower Respiratory Disorders: Overview
450
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
450